Niowave has broken ground on a $75 million production facility in Lansing to expand its manufacturing footprint and strengthen the domestic supply of Actinium‑225 (Ac‑225), a critical isotope used in next‑generation targeted cancer therapies.
The new site, Niowave’s second dedicated production facility in Lansing, will substantially increase capacity to support growing global demand for Ac-225 and other medical isotopes essential to emerging pharmaceutical treatments.
The investment will create approximately 70 highly skilled jobs; adding to Michigan’s growing advanced manufacturing and life sciences sectors. The facility will feature multiple proprietary superconducting linear accelerators along with new processing and quality systems to enable reliable, scalable production of Ac-225.
The Christman Co., in collaboration with Colliers Engineering & Design, is the contractor. The site is expected to become operational in 2028.
“This expansion reflects our continued commitment to advancing the future of targeted alpha therapy and investing in the Lansing community,” says Mike Zamaira, CEO of Niowave. “Actinium-225 has the potential to transform cancer treatment, and this new facility significantly strengthens our ability to deliver this critical isotope so that therapies can reach patients who need them.”
Ac-225 is a powerful alpha-emitting isotope central to the development of targeted cancer therapies designed to precisely destroy cancer cells while minimizing impact on healthy tissue. Interest from biopharmaceutical companies has grown rapidly, and Niowave has announced two major supply agreements in the last four months.
Founded in 2005, Niowave is a leader in developing and operating superconducting electron linear accelerators and advancing radiochemistry procedures for medical isotope production. The company produces Ac-225 and other isotopes to support the next generation of cancer treatments, with a mission to accelerate the fight against cancer through reliable, scalable supply.
For more information, visit niowaveinc.com.
, a critical isotope used in next generation targeted cancer therapies.){kind=link}